- Home
- GATX vs AKRO Comparison
GATX vs AKRO Comparison
Compare GATX & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GATX | AKRO |
|---|---|---|
| Founded | 1898 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GATX | AKRO |
|---|---|---|
| Price | $168.89 | $54.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $192.00 | $73.56 |
| AVG Volume (30 Days) | 164.0K | ★ 2.4M |
| Earning Date | 01-22-2026 | 11-07-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 8.56 | N/A |
| Revenue | ★ $1,704,900,000.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $15.03 | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.66 | N/A |
| 52 Week Low | $139.44 | $21.34 |
| 52 Week High | $178.26 | $58.40 |
Technical Indicators
Market Signals| Indicator | GATX | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 68.63 |
| Support Level | $163.47 | $54.30 |
| Resistance Level | $171.13 | $54.70 |
| Average True Range (ATR) | 3.20 | 0.17 |
| MACD | 1.14 | -0.10 |
| Stochastic Oscillator | 87.64 | 71.07 |
Price Performance
Historical ComparisonAbout GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.